Ibogaine Safety, Side Effects & Medical Protocols Explained

Transparency about ibogaine safety matters. Ibogaine is a powerful medicine that demands rigorous medical protocols; when they are followed it can be administered responsibly, and when they are skipped serious harm can result. This guide covers the safety profile, side effects, contraindications, and protocols used in ibogaine treatment at Sanctuary Tulum.

The Primary Risk: Cardiac

The main clinical concern with ibogaine is cardiac. Ibogaine prolongs the QT interval, which in susceptible individuals can lead to ventricular arrhythmias including Torsades de Pointes.¹ The risk is manageable with proper screening and monitoring — most people do not have the underlying abnormalities that make QT prolongation dangerous, but identifying those who do is non-negotiable.

The ibogaine-related deaths documented at various clinics have almost always involved skipped screening, no on-site physician, or unverified material — not ibogaine used correctly. Facility selection is a safety decision.

Sanctuary Tulum's Cardiac Safety Protocol

• 12-Lead EKG: Required before dosing. A QTc >450ms (men) or >470ms (women) is a general contraindication.
• Echocardiogram: Screens for structural abnormalities such as valve disease or cardiomyopathy.
• Electrolyte panel: Potassium and magnesium are corrected via IV before dosing if deficient.
• Continuous cardiac telemetry: Real-time monitoring across the full 24–36 hour treatment window — not periodic checks.
• On-site physician: Present in the facility during treatment, not on call by phone.
• Emergency readiness: Crash cart, defibrillator, ACLS capability, and pre-arranged hospital transfer.

Contraindications

• • Prolonged QTc on EKG (>450ms men / >470ms women)
• • Structural heart disease or history of arrhythmia
• • Severe liver disease (ibogaine is hepatically metabolized)
• • Pregnancy
• • Active psychosis or schizophrenia
• • Certain medication combinations (below)

Guests who do not pass screening are not dosed. We would rather have a difficult conversation about alternatives than compromise safety.

Medication Interactions

• Opioids: Must be tapered; methadone typically requires a 4–6 week wash-out before ibogaine is appropriate.²
• Benzodiazepines: Slow medical taper only — abrupt cessation is dangerous.
• SSRIs/SNRIs: Tapered under supervision because of serotonergic interaction risk.
• QT-prolonging drugs: Many antipsychotics, some antibiotics, and select antihistamines must be discontinued first.
• Stimulants: Cocaine, methamphetamine, and prescription stimulants must clear the system before dosing.

Common Side Effects

• Ataxia: Patients cannot walk unassisted during the acute experience; all movement is supervised.
• Nausea: Common in the first few hours; anti-nausea protocols are in place.
• Light/sound sensitivity: Treatment rooms are kept dark and quiet.
• Bradycardia: Monitored on telemetry and managed by the medical team.
• Fatigue and insomnia: 1–3 days of tiredness and sleep disruption after dosing is typical and usually self-resolving.
• Emotional sensitivity: Openness in the days after is common and part of integration.

What Rigorous Screening Actually Looks Like

A responsible ibogaine intake at Sanctuary Tulum begins weeks before arrival. Our medical team reviews the full medication list, prior cardiac history, family cardiac history, current lab work, and the reason for seeking ibogaine. Where a QTc reading, echocardiogram, or specialist clearance is needed, we arrange it in-country or coordinate with your local physician. Guests who present with an active contraindication are redirected to a safer path — often NAD+ IV therapy, tapered detox, or ayahuasca work where clinically appropriate — rather than pushed through ibogaine because they have already paid a deposit.

Aftercare and Integration

The 24–36 hour ibogaine window is only part of the treatment. The days that follow — commonly called the "grey day" and the integration week — are where much of the neurochemical repair and psychological consolidation happens. Sanctuary Tulum uses that window for continued IV support, hyperbaric oxygen sessions, structured somatic work, and one-on-one integration hours rather than sending guests home the next morning.³ Aftercare is written into the plan on arrival, not designed on the last day.

Our Safety Record

Since 2011 Sanctuary Tulum has run ibogaine programs under the protocols above and has not had a fatality during ibogaine treatment. Follow-up observational data support meaningful outcomes for opioid dependence when treatment is done properly. No provider can guarantee outcomes; transparent screening and honest disclosure are what make the treatment defensible. Ask any ibogaine clinic you consider for specifics on cardiac protocol and physician presence — and for a confidential intake conversation, contact our team. Related reading: complete guide to ibogaine treatment, what is ibogaine.

The Cardiac Question — QT Prolongation Explained

The specific cardiac risk with ibogaine is QT interval prolongation. Ibogaine and its metabolite noribogaine block the hERG potassium channel, which delays cardiac repolarization. In vulnerable patients — those with pre-existing long QT, electrolyte imbalance (low potassium, low magnesium), concurrent QT-prolonging medications, or structural heart disease — that delay can trigger torsades de pointes, a potentially fatal arrhythmia. The reported ibogaine mortality figures across unregulated settings trace almost entirely to this mechanism.

Screening addresses it directly: baseline 12-lead ECG with calculated QTc, comprehensive metabolic panel with magnesium and potassium, medication reconciliation against QT-prolonging drug lists, and continuous cardiac monitoring during administration. Sanctuary Tulum's protocol excludes guests with QTc above the standard threshold and repletes electrolytes to a target range before dosing. That is the protocol difference between a facility with an unbroken safety record and a facility that appears in the mortality literature.

Common Side Effects, Duration, and Recovery

Ataxia (unsteady coordination) and nausea are near-universal in the first 24 hours and expected. Guests are non-ambulatory during the peak and are supported through it by clinical staff. Photosensitivity and auditory sensitivity are common and are why sessions are conducted in a quiet, low-lit environment. Fatigue and appetite suppression persist for several days.

The subacute recovery window is typically 3 to 7 days. Sleep normalizes progressively. Cognitive clarity returns. Cravings for the substance of use are reported as markedly reduced — the interruption of opioid withdrawal symptoms and post-acute craving is the reason ibogaine has clinical interest at all. See ibogaine treatment.

Related: ibogaine heart safety protocol details.